Clinical Trials

320 enrolled

Carcinoma, Transitional Cell

NCT05633667 2026-03-17

VELOCITY-Lung

270 enrolled

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT06161532 2026-03-17

Sacituzumab Govitecan With or Without Atezolizumab Immunotherapy in Rare Genitourinary Tumors (SMART) Such as High Grade Neuroendocrine Carcinomas, Adenocarcinoma, and Squamous Cell Bladder/Urinary Tract Cancer, Renal Medullary Carcinoma and Penile C...

60 enrolled

Carcinoma, Transitional Cell

NCT03424005 2026-03-16

Morpheus-panBC

792 enrolled

Breast Neoplasms

NCT03547973 2026-03-16

TROPHY U-01

827 enrolled 1 FDA

Metastatic Urothelial Cancer

NCT05833867 2026-03-13

Adaptive RADiation Therapy With Concurrent Sacituzumab Govitecan (SG) for Muscle Invasive Bladder Cancer

Localized Muscle Invasive Bladder Urothelial Carcinoma

NCT05884320 2026-03-11

Phase II Trial of Sacituzumab Govitecan in Recurrent and/or Metastatic Secretory Gland Cancers

30 enrolled

Head & Neck

Salivary Gland Neoplasms

NCT06311214 2026-03-06

Personalized Antibody-Drug Conjugate Therapy Based on RNA and Protein Testing for the Treatment of Advanced or Metastatic Solid Tumors (The ADC MATCH Screening and Treatment Trial)

500 enrolled

Tumor-Agnostic

Neoplasm Metastasis

NCT04468061 2026-02-27

Sacituzumab Govitecan +/- Pembrolizumab in Metastatic TNBC

110 enrolled

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT05581589 2026-02-27

Sacituzumab Govitecan Before Radical Cystectomy for the Treatment of Non-Urothelial Muscle Invasive Bladder Cancer

18 enrolled

Urinary Bladder Neoplasms

NCT07063212 2026-02-19

A Study of Sacituzumab Govitecan in Combination With Cetuximab in People With Head and Neck Squamous Cell Cancer (HNSCC)

40 enrolled

Head & Neck

Squamous Cell Carcinoma of Head and Neck, Hypopharyngeal Neoplasms, Laryngeal Neoplasms, Mouth Neoplasms, Oropharyngeal Neoplasms

NCT06963905 2026-02-17

SIMONE

60 enrolled

Triple Negative Breast Neoplasms

NCT04617522 2026-02-11

Study of Sacituzumab Govitecan in Participants With Advanced or Metastatic Solid Tumor and Moderate Liver Impairment

30 enrolled

Neoplasm Metastasis, Liver Failure

NCT05838521 2026-02-06

A Study of Sacituzumab Govitecan (IMMU-132) in Patients With Recurrent or Persistent Cervical Cancer

Gynecologic

Uterine Cervical Neoplasms

NCT06926920 2026-01-30

A Study of Sacituzumab Govitecan Given at an Alternative Dose and Schedule in Participants With Advanced Triple-Negative Breast Cancer

100 enrolled

Triple Negative Breast Neoplasms

NCT07339059 2026-01-30

SG and Immunotherapy as Maintenance Therapy for Extensive-stage Small-cell Lung Cancer

35 enrolled

Lung Neoplasms, Small Cell Lung Carcinoma

NCT05633654 2026-01-20

Study of Sacituzumab Govitecan-hziy and Pembrolizumab Versus Treatment of Physician's Choice in Patients With Triple Negative Breast Cancer Who Have Residual Invasive Disease After Surgery and Neoadjuvant Therapy (ASCENT-05/AFT-65 OptimICE-RD/GBG 119/NSABP B-63)

1,514 enrolled

Triple Negative Breast Neoplasms

NCT06263543 2025-12-26

SERIES

75 enrolled

Breast Neoplasms

NCT06065371 2025-12-19

Sacituzumab Govitecan in Combination With Capecitabine for Advanced Gastrointestinal Cancers After Progression on Standard Therapy

Gastrointestinal

Biliary Tract Neoplasms, Esophageal Neoplasms, Gastrointestinal Neoplasms, Pancreatic Neoplasms, Stomach Neoplasms, Colorectal Neoplasms

NCT06238921 2025-12-05

Sacituzumab Govitecan and Zimberelimab w/SRS in the Management of Metastatic Triple Negative Breast Cancer With Brain Metastases

31 enrolled

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT06409390 2025-12-04

Sequential Therapies Modeled on Evolutionary Dynamics for Breast Cancer

15 enrolled

Breast Neoplasms

NCT06040970 2025-12-02

Sacituzumab Govitecan in Combination With Cisplatin in Platinum Sensitive Recurrent Ovarian and Endometrial Cancer

54 enrolled

Gynecologic

Ovarian Neoplasms, Uterine Neoplasms

NCT04986579 2025-11-19

Scalp Cooling in MBC

120 enrolled

Breast Neoplasms

NCT05867251 2025-11-19

Study of AVZO-021 in Patients With Advanced Solid Tumors

430 enrolled

BreastGynecologic

Carcinoma, Ovarian Epithelial, Breast Neoplasms, Fallopian Tube Neoplasms, Endometrial Neoplasms, Triple Negative Breast Neoplasms

NCT06081244 2025-11-19

ADAPT-TN-III

348 enrolled

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT04794699 2025-11-12

Study of IDE397 in Participants With Solid Tumors Harboring MTAP Deletion

180 enrolled

GenitourinaryThoracic

Urinary Bladder Neoplasms, Lung Neoplasms

NCT04724018 2025-11-04

Sacituzumab Govitecan Plus EV in Metastatic UC

106 enrolled

Urinary Bladder Neoplasms, Carcinoma, Transitional Cell

NCT07011654 2025-10-23

Study of Naxitamab and Sacituzumab Govitecan in Patients With Metastatic Triple-negative Breast Cancer (TNBC)

31 enrolled

Triple Negative Breast Neoplasms

NCT04230109 2025-10-14

NeoSTAR

260 enrolled

Triple Negative Breast Neoplasms

NCT06462092 2025-09-29

Sacituzumab Govitecan and Intrathecal Chemotherapy for Treating Leptomeningeal Metastases From Her2-negative Breast Cancer

34 enrolled

BreastCNS

Breast Neoplasms, Meningeal Carcinomatosis

NCT06827613 2025-09-24

START-002

50 enrolled

Triple Negative Locally Advanced Non-resectable Breast Cancer

NCT04434040 2025-08-19

Atezolizumab + Sacituzumab Govitecan to Prevent Recurrence in TNBC (ASPRIA)

40 enrolled

Breast Neoplasms, Neoplasm, Residual, Triple Negative Breast Neoplasms

NCT04559230 2025-08-05

Sacituzumab Govitecan in Recurrent Glioblastoma

32 enrolled

CNS

Glioblastoma

NCT06923826 2025-07-25

TROP2

32 enrolled

Head & Neck

Salivary Gland Neoplasms, Thyroid Neoplasms

NCT07046455 2025-07-01

Trop-2 Targeted PET Probes in Advanced TNBC

Phase NA Recruiting

Triple Negative Breast Neoplasms

NCT06665178 2025-06-25

Genomic and Transcriptomic Predictors of Sequential SG Sensitivity After T-DXd in ER+/HER2-Low Metastatic Breast Cancer

Breast Neoplasms

NCT05552001 2025-06-11

ISIdE

96 enrolled

Breast Neoplasms, Neoplasm Metastasis, Triple Negative Breast Neoplasms

NCT05226117 2025-06-03

Sacituzumab Govitecan, Preceding Radical Cystectomy, in Treating Patients With Muscle-invasive Bladder Cancer

44 enrolled

Carcinoma, Transitional Cell

NCT06055465 2025-05-15

Neoadjuvant Sacituzumab Govitecan Plus Pembrolizumab in Resectable Non-Small Cell Lung Cancer

37 enrolled

Lung Neoplasms

NCT06401824 2025-05-06

Sacituzumab Govitecan and Bevacizumab for NSCLC Brain Metastases

25 enrolled

CNSThoracic

Brain Neoplasms, Carcinoma, Non-Small-Cell Lung

NCT03971409 2025-05-02

InCITe

150 enrolled

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT06431633 2025-04-10

ARIAN

129 enrolled

Carcinoma, Non-Small-Cell Lung, Lung Diseases

NCT05770531 2025-04-04

Circulating Tumor DNA to Guide Changes in Standard of Care Chemotherapy

160 enrolled

Triple Negative Breast Neoplasms

NCT06682728 2025-03-26

Adjuvant Sacituzumab Govitecan and Nivolumab in Muscle-Invasive Urothelial Carcinoma At High-Risk Recurrence

23 enrolled

Carcinoma, Transitional Cell

NCT05332561 2025-03-20

Genomics Guided Targeted Post-neoadjuvant Therapy in Patients With Early Breast Cancer (COGNITION-GUIDE)

240 enrolled

Breast Neoplasms

NCT06167317 2025-03-12

Study of GS-0201 Alone and in Combination in Participants With Advanced Solid Tumors

254 enrolled

Other solid neoplasm

Advanced Solid Tumors

NCT06667167 2025-01-17

First Line Therapy for Extensive SCLC Patients, Treated with Chemo+Keytruda Followed by Keytuda+Trodelvy

21 enrolled

Carcinoma, Non-Small-Cell Lung

NCT06329869 2024-12-02

SG-ESCC

35 enrolled

Gastrointestinal

Esophageal Squamous Cell Carcinoma

NCT06102824 2024-11-25

ORIENTA

252 enrolled

HER2-negative Breast Cancer

NCT06235216 2024-11-01

SETHY